medigraphic.com

2019, Number 3

<< Back Next >>

Rev Hematol Mex 2019; 20 (3)

Blinatumomab before haploidentical transplant in a child with refractory acute lymphoblastic leukemia

Olaya-Vargas A, Rivera-Luna R, Melchor-Vidal Y, Cedeño-Cuellar C, Salazar-Rosales H, Olaya-Nieto A

Language: English
References: 11
Page: 235-239
PDF size: 266.42 Kb.


ABSTRACT

The case of a 10-year-old patient with refractory pre-B acute lymphoblastic leukemia (ALL) who received two cycles of blinatumomab at 10 µg/m2, escalating up to 15 µg/ m2, is described. At the end of the second cycle, complete hematological remission was achieved, as evidenced by cytomorphology and minimal residual disease. Afterward, the patient received a haploidentical transplant from a paternal donor and cyclophosphamide therapy for consolidation; currently, she is at +365 days from transplant and in complete remission with 100% complete chimerism. The patient presented with late cytokine release syndrome as a side effect of blinatumomab and acute graft-versushost disease grade III, both of which were successfully treated, and the patient remains asymptomatic.


REFERENCES

  1. Hunger SP, Mullighan CG. Acute Lymphoblastic Leukemia in Children. N Engl J Med 2015;373:1541-52.

  2. Hunger SP, Lu X, Devidas M, Camitta BM, Gaynon PS, Winick NJ, et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the Children´s Oncology Group. J Clin Oncol 2012;30(14):1663-69.

  3. Madhusoodhan PP, Carroll WL, Bhatla T. Progress and prospects in pediatric leukemia. Curr Probl Pediatr Adolesc Health Care 2016;46:229-41.

  4. Majhail NS, Farnia SH, Carpenter PA, Champlin RE, Crawford S, Marks DI, et al. Indications for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2015;21:1863-1869.

  5. Klingebiel T, Cornish J, Labopin M, Locatelli F, Darbyshire P, Handgretinger R, et al. Results and factors influencing outcome after fully haploidentical hematopoietic stem cell transplantation in children with very high-risk acute lymphoblastic leukemia: impact of center size: an analysis on behalf of the Acute Leukemia and Pediatric Disease Working Parties of the European Blood and Marrow Transplantation. Blood 2010;115:3437-3446.

  6. Von Stackelberg A, Locatelli F, Zugmaier G, Handgretinger R, Trippett TM, Rizzari C, et al. Phase I/phase II study of blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. J Clin Oncol 2016;34(36):1-9.

  7. Matthew J Newman, Dina J Benani. A review of blinatumomab, a novel immunotherapy. J Oncol Pharm Practice 2016;22:639-645.

  8. Mehta P, Davies M. Hematopoietic cell transplantation for acute lymphoblastic leukemia in children. In: Forman S, Negrin R, Antin JH, Appelbaum FR. Thomas’ Hematopoietic cell transplantation. 5th ed. CA, USA: John Wiley & Sons, 2016;600-613.

  9. Reisner Y, Aversa F, Martelli MF. Haploidentical hematopoietic stem cell transplantation: state of the art. Bone Marrow Transplant 2015;50(2):S1-S5.

  10. Luznik L, Bolaños-Meade J, Zahurak M, Chen AR, B. Smith D, Brodsky R, et al. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood 2010;115(16):3224-3230.

  11. Berger M, Lanino E, Cesaro S, Zecca M, Vasallo E, Faraci M, et al. Feasibility and outcome of haploidentical hematopoietic stem cell transplantation with post-transplant high-dose cyclophosphamide for children and adolescents with hematologic malignancies: An AIEOP-GITMO Retrospective Multicenter Study. Biol Blood Marrow Transplant 2016;22:902-09.




2020     |     www.medigraphic.com